Chemotherapy plus RA223 in the treatment of oat cell lung cancer

Allan Lipton, Harold Harvey, B. Walker, R. Dixon, D. Valdivia, S. Barnes, R. Gordon, D. White-Hershey, M. J. Bartholomew, N. Warzawski, C. E. Antle

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

One hundred and one patients with oat (small) cell lung cancer have been treated with CAVE [Cytoxan, Adriamycin, Vicristine, and etoposide (VP-16)] chemotherapy ± RA233 (a platelet-inhibiting agent). There was no difference in disease-free interval, pattern of relapse, or survival between groups.

Original languageEnglish (US)
Pages (from-to)259-263
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume12
Issue number3
DOIs
StatePublished - Jan 1 1989

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Drug Therapy
Doxorubicin
Cyclophosphamide
Blood Platelets
Recurrence
Survival
Therapeutics
EVAC protocol

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lipton, Allan ; Harvey, Harold ; Walker, B. ; Dixon, R. ; Valdivia, D. ; Barnes, S. ; Gordon, R. ; White-Hershey, D. ; Bartholomew, M. J. ; Warzawski, N. ; Antle, C. E. / Chemotherapy plus RA223 in the treatment of oat cell lung cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1989 ; Vol. 12, No. 3. pp. 259-263.
@article{df96015a6be44c668d58670860015cea,
title = "Chemotherapy plus RA223 in the treatment of oat cell lung cancer",
abstract = "One hundred and one patients with oat (small) cell lung cancer have been treated with CAVE [Cytoxan, Adriamycin, Vicristine, and etoposide (VP-16)] chemotherapy ± RA233 (a platelet-inhibiting agent). There was no difference in disease-free interval, pattern of relapse, or survival between groups.",
author = "Allan Lipton and Harold Harvey and B. Walker and R. Dixon and D. Valdivia and S. Barnes and R. Gordon and D. White-Hershey and Bartholomew, {M. J.} and N. Warzawski and Antle, {C. E.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1097/00000421-198906000-00016",
language = "English (US)",
volume = "12",
pages = "259--263",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Lipton, A, Harvey, H, Walker, B, Dixon, R, Valdivia, D, Barnes, S, Gordon, R, White-Hershey, D, Bartholomew, MJ, Warzawski, N & Antle, CE 1989, 'Chemotherapy plus RA223 in the treatment of oat cell lung cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 12, no. 3, pp. 259-263. https://doi.org/10.1097/00000421-198906000-00016

Chemotherapy plus RA223 in the treatment of oat cell lung cancer. / Lipton, Allan; Harvey, Harold; Walker, B.; Dixon, R.; Valdivia, D.; Barnes, S.; Gordon, R.; White-Hershey, D.; Bartholomew, M. J.; Warzawski, N.; Antle, C. E.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 12, No. 3, 01.01.1989, p. 259-263.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemotherapy plus RA223 in the treatment of oat cell lung cancer

AU - Lipton, Allan

AU - Harvey, Harold

AU - Walker, B.

AU - Dixon, R.

AU - Valdivia, D.

AU - Barnes, S.

AU - Gordon, R.

AU - White-Hershey, D.

AU - Bartholomew, M. J.

AU - Warzawski, N.

AU - Antle, C. E.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - One hundred and one patients with oat (small) cell lung cancer have been treated with CAVE [Cytoxan, Adriamycin, Vicristine, and etoposide (VP-16)] chemotherapy ± RA233 (a platelet-inhibiting agent). There was no difference in disease-free interval, pattern of relapse, or survival between groups.

AB - One hundred and one patients with oat (small) cell lung cancer have been treated with CAVE [Cytoxan, Adriamycin, Vicristine, and etoposide (VP-16)] chemotherapy ± RA233 (a platelet-inhibiting agent). There was no difference in disease-free interval, pattern of relapse, or survival between groups.

UR - http://www.scopus.com/inward/record.url?scp=0024391620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024391620&partnerID=8YFLogxK

U2 - 10.1097/00000421-198906000-00016

DO - 10.1097/00000421-198906000-00016

M3 - Article

C2 - 2543207

AN - SCOPUS:0024391620

VL - 12

SP - 259

EP - 263

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -